Ponatinib for the treatment of chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

Drugs of Today

Volumn 49, Issue 4, 2013, Pages 261-269

  Narayanan, V ^a   Pollyea, D A ^a   Gutman, J A ^a   Jimeno, A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; Chronic myeloid leukemia; Ponatinib; T315I mutation; Tyrosine kinase inhibitor

Indexed keywords

BOSUTINIB; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PONATINIB;

ACNE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG METABOLISM; DRUG SAFETY; DRY SKIN; FATIGUE; HUMAN; NAUSEA; NONHUMAN; PANCREATITIS; PHILADELPHIA CHROMOSOME POSITIVE CELL; RASH; SIDE EFFECT;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; PONATINIB; T315I MUTATION; TYROSINE KINASE INHIBITOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDAZINES;

EID: 84877839495     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.4.1950147     Document Type: Article

References (45)

1. Nowell, P.C., Hungerford, D.A. A minute chromosome in human granulocytic leukemia. Science 1960, 142:1497.
2. Rowley, J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243(5405): 290-3.
3. Kurzrock, R., Kantarjian, H.M., Druker, B.J., Talpaz, M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003, 138(10): 819-30.
4. Daley, G.Q., Van Etten, R.A., Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247(4944): 824-30.
5. Propp, S., Lizzi, F.A. Philadelphia chromosome in acute lymphocytic leukemia. Blood 1970, 36(3): 353-60.
6. Faderl, S., Garcia-Manero, G., Thomas, D.A., Kantarjian, H.M. Philadelphia chromosome-positive acute lymphoblastic leukemia-current concepts and future perspectives. Rev Clin Exp Hematol 2002, 6(2): 142-60; discussion 200-2.
7. Van Etten, R.A. Disease progression in a murine model of bcr/abl leukemogenesis. Leuk Lymphoma 1993, 11(Supp. 1): 239-42.
8. Siegel, R., Naishadham, D., Jemal, A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1): 10-29.
9. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., Kantarjian, H.M. The biology of chronic myeloid leukemia. N Engl J Med 1999, 341(3): 164-72.
10. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T, Thun, M.J. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2): 71-96.
11. Westbrook, CA., Hooberman, A.L., Spino, C. et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992, 80(12): 2983-90.
12. Secker-Walker, L.M., Craig, J.M., Hawkins, J.M., Hoffbrand, A.V Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 1991, 5(3): 196-9.
13. Liu-Dumlao, T, Kantarjian, H., Thomas, D.A., O'Brien, S., Ravandi, F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep 2012, 14(5): 387-94.
14. Druker, B.J., Tamura, S., Buchdunger, E. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2(5): 561-6.
15. Vigneri, P., Wang, J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001, 7(2): 228-34.
16. Highlights of prescribing information: Imatinib mesylate [package insert] 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/021588s024lbl. pdf. Accessed February, 2013.
17. O'Brien, S.G., Guilhot, F., Larson, R.A. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(11): 994-1004.
18. Druker, B.J., Guilhot, F, O'Brien, S.G. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23): 2408-17.
19. Druker, B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112(13): 4808-17.
20. de Lavallade, H., Apperley, J.F, Khorashad, J.S. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intentionto-treat analysis. J Clin Oncol 2008, 26(20): 3358-63.
21. Ottmann, O.G., Druker, B.J., Sawyers, C.L. et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100(6): 1965-71.
22. Hochhaus, A., O'Brien, S.G., Guilhot, F et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23(6): 1054-61.
23. Kantarjian, H., Shah, N.R, Hochhaus, A. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362(24): 2260-70.
24. Saglio, G., Kim, D.W., Issaragrisil, S. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362(24): 2251-9.
25. Cortes, J.E., Kim, D.W., Kantarjian, H.M. et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012, 30(28): 3486-92.
26. Cortes, J., Lipton, J.H., Rea, D. et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with 73)5/mutation. Blood 2012, 120(13): 2573-80.
27. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., Sawyers, C.L. Clinical resistance to ST1-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293(5531): 876-80.
28. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., Sawyers, C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2(2): 117-25.
29. Bixby, D., Talpaz, M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 2009: 461-76.
30. Mathisen, M.S., Kantarjian, H.M., Cortes, J., Jabbour, E. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica 2011, 96(3): 347-9.
31. O'Hare, T., Eide, CA., Deininger, M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110(7): 2242-9.
32. ARIAD announces that Iclusig™ (ponatinib) receives positive CHMP opinion for approval in the European Union [news release]. ARIAD Pharmaceuticals, Inc., March 22, 2013. Accessed April 15, 2013.
33. Zhou, T., Commodore, L., Huang, W.S. et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011, 77(1): 1-11.
34. O'Hare, T., Shakespeare, W.C., Zhu, X. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the 73)5/mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16(5): 401-12.
35. Cassuto, O., Duties, M., Jacquel, A. et al. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib. Oncotarget 2012, 3(12): 1557-65.
36. Highlights of prescribing information: Ponatinib [package insert] 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203469lbl.pdf. Accessed February, 2013.
37. Cortes, J.E., Kantarjian, H., Shah, N.P. et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012, 367(22): 2075-88.
38. Druker, B.J., Talpaz, M., Resta, D.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(14): 1031-7.
39. Cortes, J.E., Kim, D.-W., Pinilla-Ibarz, J., et al. Initial findings from the PACE trial: A pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the 73)5/mutation. Blood [53rd Annu Meet Am Soc Hematol (Dec 10-13, San Diego) 2011] 2011, 118(21): Abst 109.
40. Cortes, J.E., Kim, D.-W., Pinilla-Ibarz, J., et al. PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the 73/5/mutation. J Clin Oncol [48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(SuppL): Abst 6503.
41. ClinicalTrials.gov Web site, http://www.clinicaltrials.gov/ct2/results? term=ponatinib. Accessed February 10, 2013.
42. Pemmaraju, N., Parikh, S.A., Jabbour, E., Kantarjian, H.M., Cortes, J. Chronic myeloid leukemia. In: Vol. The MD Anderson Manual of Medical Oncology 2nd Edition. R.A. Wolff, Koller, CA. (Ed.). McGraw-Hill Press: Houston 2012, 60.
43. Reddy, E.P., Aggarwal, A.K. The ins and outs of bcr-abl inhibition. Genes Cancer 2012, 3(5-6): 447-54.
44. Ohanian, M., Cortes, J., Kantarjian, H., Jabbour, E. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother 2012, 13(7): 927-38.
45. Redaelli, S., Piazza, R., Rostagno, R. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009, 27(3): 469-71.